The FDA has introduced a framework for accelerating the development of individualized therapies, particularly for ultra-rare diseases. This "plausible mechanism framework" may apply to more than just bespoke gene therapies, and its principles are not exclusive to this area. The framework's details and potential impact are still being discussed, with some former officials proposing changes and others considering its potential to advance rare disease drug development.